

May 22, 2002

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835

\mathbb{D}	ECEIVE	Ī
M	MAY 2 3 2002	

RE: Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a manufacturer and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ostivone®	Ipriflavone	Ostivone enhances the body's absorption and use of calcium, and is most beneficial when taken with a calcium-rich, multi-nutrient bone support product such as Doctor's Choice for Bone Health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert C. Doster Title: Senior Vice President of Scientific Affairs

Date: 5.22.02

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

Never P

825 Challenger Drive Green Bay, WI 54311-8328 Ph[.] 920-469-1313 Fax. 888-570-6460 www.enzy.com

Michael P. Devereux Chief Financial Officer

Ostivone 2e

975 0162

LET 10139

7642